- Binder H, Dittrich R, Einhaus F, Krieg J, Müller A, et al. (2007a) Update on ovarian hyperstimulation syndrome: Part 1--Incidence and pathogenesis. Int J Fertil Womens Med 52: 11-26.
- Brinsden PR, Wada I, Tan SL et al. Review: diagnosis, prevention and management of ovarian hyperstimulation syndrome. Br J Obstet Gynaecol 1995; 102: 767–772.
- Chan WS. (2009) The ‘ART’ of thrombosis: a review of arterial and venous thrombosis in assisted reproductive technology. Curr Opin Obstet Gynecol 21: 207–218.
- Davies MG, Hagen PO. Systemic inflammatory response syndrome. Br J Surg. 1997; 84: 920–935.
- Ferraretti AP, Goossens V, de Mouzon J, Bhattacharya S, Castilla JA, Korsak V, Kupka M, Nygren KG, Nyboe Andersen A: Assisted reproductive technology in Europe, 2008: results generated from European registers by ESHRE. Hum Reprod 2012, 27(9):2571–2584.
- Humaidan P, Quartarolo J, Papanikolaou EG. (2010) Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril 94: 389-400.
- McClure N, Healy DL, Rogers PAW, Sullivan J, Beaton L, Haning Jr RV, et al. (1994) Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 344: 235-236.
- Polishuk WZ, Schenker JG. (1969) Ovarian overstimulation syndrome. Fertil Steril 20: 443–450.
ООО «МСД Фармасьютикалс»,
Россия, 115093, г. Москва, Павловская, д. 7, стр. 1, Tел.: +7 (495) 916 71 00, Факс: +7 (495) 916 70 94, www.merck.com
WOMN-1067734-0000; 01.2013
Данная информация предоставлена МСД в качестве информационной поддержки врачам.
Информация, относящаяся к какому-либо лекарственному препарату(ам) может не соответствовать утвержденной инструкции по применению.